Sharps CEO issues letter to shareholders with details about the InjectEZ acquisition, establishing Sharps position in the prefillable syringe (PFS) industry in the U.S.
Signed Syringe Sales Agreement will secure product orders totaling over $200 million for the first five years of operation.
Sharps is negotiating additional pharma-segment purchase commitments for orders over the next three years, with shipments expected to begin by Q2 of 2025.
Demand for Sharps products is increasing due to recent FDA warnings, tariffs, and healthcare's move away from glass syringes.